 | • レポートコード：MRC2-11QY11673 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は拡張型心筋症治療のグローバル市場について調査・分析したレポートです。種類別（薬物、植込み型除細動器）市場規模、用途別（病院・クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別拡張型心筋症治療の競争状況、市場シェア ・世界の拡張型心筋症治療市場：種類別市場規模 2015年-2020年（薬物、植込み型除細動器） ・世界の拡張型心筋症治療市場：種類別市場規模予測 2021年-2026年（薬物、植込み型除細動器） ・世界の拡張型心筋症治療市場：用途別市場規模 2015年-2020年（病院・クリニック、その他） ・世界の拡張型心筋症治療市場：用途別市場規模予測 2021年-2026年（病院・クリニック、その他） ・北米の拡張型心筋症治療市場分析：米国、カナダ ・ヨーロッパの拡張型心筋症治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの拡張型心筋症治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の拡張型心筋症治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの拡張型心筋症治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：GlaxoSmithKline、Pfizer、Novartis、Merck、Janssen Pharmaceuticals、AstraZeneca、Array BioPharma、Vericel、Celladon、Teva Pharmaceutical Industries ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Dilated Cardiomyopathy (DCM) is a condition in which heart’s left ventricle, is enlarged and weakened and the ability to pump blood is decreased.
The growth in DCM treatment market is due to prominent rise in number of heart failure patients worldwide over the years, R&D activities and increased awareness for timely diagnosis.
Market Analysis and Insights: Global Dilated Cardiomyopathy Treatment Market
The global Dilated Cardiomyopathy Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Dilated Cardiomyopathy Treatment Scope and Market Size
Dilated Cardiomyopathy Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Dilated Cardiomyopathy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
GlaxoSmithKline
Pfizer
Novartis
Merck
Janssen Pharmaceuticals
AstraZeneca
Array BioPharma
Vericel
Celladon
Teva Pharmaceutical Industries
Market segment by Type, the product can be split into
Drugs
Implantable Devices
Market segment by Application, split into
Hospitals and Clinics
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Dilated Cardiomyopathy Treatment Revenue
1.4 Market by Type
1.4.1 Global Dilated Cardiomyopathy Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Drugs
1.4.3 Implantable Devices
1.5 Market by Application
1.5.1 Global Dilated Cardiomyopathy Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals and Clinics
1.5.3 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Dilated Cardiomyopathy Treatment Market Perspective (2015-2026)
2.2 Global Dilated Cardiomyopathy Treatment Growth Trends by Regions
2.2.1 Dilated Cardiomyopathy Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Dilated Cardiomyopathy Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Dilated Cardiomyopathy Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Dilated Cardiomyopathy Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Dilated Cardiomyopathy Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Dilated Cardiomyopathy Treatment Players by Market Size
3.1.1 Global Top Dilated Cardiomyopathy Treatment Players by Revenue (2015-2020)
3.1.2 Global Dilated Cardiomyopathy Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Dilated Cardiomyopathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Dilated Cardiomyopathy Treatment Market Concentration Ratio
3.2.1 Global Dilated Cardiomyopathy Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Dilated Cardiomyopathy Treatment Revenue in 2019
3.3 Dilated Cardiomyopathy Treatment Key Players Head office and Area Served
3.4 Key Players Dilated Cardiomyopathy Treatment Product Solution and Service
3.5 Date of Enter into Dilated Cardiomyopathy Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Dilated Cardiomyopathy Treatment Historic Market Size by Type (2015-2020)
4.2 Global Dilated Cardiomyopathy Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)
5.2 Global Dilated Cardiomyopathy Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Dilated Cardiomyopathy Treatment Market Size (2015-2020)
6.2 Dilated Cardiomyopathy Treatment Key Players in North America (2019-2020)
6.3 North America Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020)
6.4 North America Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Dilated Cardiomyopathy Treatment Market Size (2015-2020)
7.2 Dilated Cardiomyopathy Treatment Key Players in Europe (2019-2020)
7.3 Europe Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020)
7.4 Europe Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)
8 China
8.1 China Dilated Cardiomyopathy Treatment Market Size (2015-2020)
8.2 Dilated Cardiomyopathy Treatment Key Players in China (2019-2020)
8.3 China Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020)
8.4 China Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Dilated Cardiomyopathy Treatment Market Size (2015-2020)
9.2 Dilated Cardiomyopathy Treatment Key Players in Japan (2019-2020)
9.3 Japan Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020)
9.4 Japan Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Dilated Cardiomyopathy Treatment Market Size (2015-2020)
10.2 Dilated Cardiomyopathy Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)
11 India
11.1 India Dilated Cardiomyopathy Treatment Market Size (2015-2020)
11.2 Dilated Cardiomyopathy Treatment Key Players in India (2019-2020)
11.3 India Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020)
11.4 India Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Dilated Cardiomyopathy Treatment Market Size (2015-2020)
12.2 Dilated Cardiomyopathy Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020)
12.4 Central & South America Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Details
13.1.2 GlaxoSmithKline Business Overview
13.1.3 GlaxoSmithKline Dilated Cardiomyopathy Treatment Introduction
13.1.4 GlaxoSmithKline Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020))
13.1.5 GlaxoSmithKline Recent Development
13.2 Pfizer
13.2.1 Pfizer Company Details
13.2.2 Pfizer Business Overview
13.2.3 Pfizer Dilated Cardiomyopathy Treatment Introduction
13.2.4 Pfizer Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.2.5 Pfizer Recent Development
13.3 Novartis
13.3.1 Novartis Company Details
13.3.2 Novartis Business Overview
13.3.3 Novartis Dilated Cardiomyopathy Treatment Introduction
13.3.4 Novartis Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.3.5 Novartis Recent Development
13.4 Merck
13.4.1 Merck Company Details
13.4.2 Merck Business Overview
13.4.3 Merck Dilated Cardiomyopathy Treatment Introduction
13.4.4 Merck Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.4.5 Merck Recent Development
13.5 Janssen Pharmaceuticals
13.5.1 Janssen Pharmaceuticals Company Details
13.5.2 Janssen Pharmaceuticals Business Overview
13.5.3 Janssen Pharmaceuticals Dilated Cardiomyopathy Treatment Introduction
13.5.4 Janssen Pharmaceuticals Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.5.5 Janssen Pharmaceuticals Recent Development
13.6 AstraZeneca
13.6.1 AstraZeneca Company Details
13.6.2 AstraZeneca Business Overview
13.6.3 AstraZeneca Dilated Cardiomyopathy Treatment Introduction
13.6.4 AstraZeneca Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.6.5 AstraZeneca Recent Development
13.7 Array BioPharma
13.7.1 Array BioPharma Company Details
13.7.2 Array BioPharma Business Overview
13.7.3 Array BioPharma Dilated Cardiomyopathy Treatment Introduction
13.7.4 Array BioPharma Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.7.5 Array BioPharma Recent Development
13.8 Vericel
13.8.1 Vericel Company Details
13.8.2 Vericel Business Overview
13.8.3 Vericel Dilated Cardiomyopathy Treatment Introduction
13.8.4 Vericel Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.8.5 Vericel Recent Development
13.9 Celladon
13.9.1 Celladon Company Details
13.9.2 Celladon Business Overview
13.9.3 Celladon Dilated Cardiomyopathy Treatment Introduction
13.9.4 Celladon Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.9.5 Celladon Recent Development
13.10 Teva Pharmaceutical Industries
13.10.1 Teva Pharmaceutical Industries Company Details
13.10.2 Teva Pharmaceutical Industries Business Overview
13.10.3 Teva Pharmaceutical Industries Dilated Cardiomyopathy Treatment Introduction
13.10.4 Teva Pharmaceutical Industries Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020)
13.10.5 Teva Pharmaceutical Industries Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Dilated Cardiomyopathy Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Dilated Cardiomyopathy Treatment Revenue
Table 3. Ranking of Global Top Dilated Cardiomyopathy Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Dilated Cardiomyopathy Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Drugs
Table 6. Key Players of Implantable Devices
Table 7. Global Dilated Cardiomyopathy Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Dilated Cardiomyopathy Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Dilated Cardiomyopathy Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Dilated Cardiomyopathy Treatment Market Share by Regions (2015-2020)
Table 11. Global Dilated Cardiomyopathy Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Dilated Cardiomyopathy Treatment Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Dilated Cardiomyopathy Treatment Market Growth Strategy
Table 17. Main Points Interviewed from Key Dilated Cardiomyopathy Treatment Players
Table 18. Global Dilated Cardiomyopathy Treatment Revenue by Players (2015-2020) (Million US$)
Table 19. Global Dilated Cardiomyopathy Treatment Market Share by Players (2015-2020)
Table 20. Global Top Dilated Cardiomyopathy Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dilated Cardiomyopathy Treatment as of 2019)
Table 21. Global Dilated Cardiomyopathy Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Dilated Cardiomyopathy Treatment Product Solution and Service
Table 24. Date of Enter into Dilated Cardiomyopathy Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 27. Global Dilated Cardiomyopathy Treatment Market Size Share by Type (2015-2020)
Table 28. Global Dilated Cardiomyopathy Treatment Revenue Market Share by Type (2021-2026)
Table 29. Global Dilated Cardiomyopathy Treatment Market Size Share by Application (2015-2020)
Table 30. Global Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 31. Global Dilated Cardiomyopathy Treatment Market Size Share by Application (2021-2026)
Table 32. North America Key Players Dilated Cardiomyopathy Treatment Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Dilated Cardiomyopathy Treatment Market Share (2019-2020)
Table 34. North America Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 35. North America Dilated Cardiomyopathy Treatment Market Share by Type (2015-2020)
Table 36. North America Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 37. North America Dilated Cardiomyopathy Treatment Market Share by Application (2015-2020)
Table 38. Europe Key Players Dilated Cardiomyopathy Treatment Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Dilated Cardiomyopathy Treatment Market Share (2019-2020)
Table 40. Europe Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Dilated Cardiomyopathy Treatment Market Share by Type (2015-2020)
Table 42. Europe Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Dilated Cardiomyopathy Treatment Market Share by Application (2015-2020)
Table 44. China Key Players Dilated Cardiomyopathy Treatment Revenue (2019-2020) (Million US$)
Table 45. China Key Players Dilated Cardiomyopathy Treatment Market Share (2019-2020)
Table 46. China Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 47. China Dilated Cardiomyopathy Treatment Market Share by Type (2015-2020)
Table 48. China Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 49. China Dilated Cardiomyopathy Treatment Market Share by Application (2015-2020)
Table 50. Japan Key Players Dilated Cardiomyopathy Treatment Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Dilated Cardiomyopathy Treatment Market Share (2019-2020)
Table 52. Japan Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Dilated Cardiomyopathy Treatment Market Share by Type (2015-2020)
Table 54. Japan Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Dilated Cardiomyopathy Treatment Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Dilated Cardiomyopathy Treatment Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Dilated Cardiomyopathy Treatment Market Share (2019-2020)
Table 58. Southeast Asia Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Dilated Cardiomyopathy Treatment Market Share by Type (2015-2020)
Table 60. Southeast Asia Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Dilated Cardiomyopathy Treatment Market Share by Application (2015-2020)
Table 62. India Key Players Dilated Cardiomyopathy Treatment Revenue (2019-2020) (Million US$)
Table 63. India Key Players Dilated Cardiomyopathy Treatment Market Share (2019-2020)
Table 64. India Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 65. India Dilated Cardiomyopathy Treatment Market Share by Type (2015-2020)
Table 66. India Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 67. India Dilated Cardiomyopathy Treatment Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Dilated Cardiomyopathy Treatment Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Dilated Cardiomyopathy Treatment Market Share (2019-2020)
Table 70. Central & South America Dilated Cardiomyopathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Dilated Cardiomyopathy Treatment Market Share by Type (2015-2020)
Table 72. Central & South America Dilated Cardiomyopathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Dilated Cardiomyopathy Treatment Market Share by Application (2015-2020)
Table 74. GlaxoSmithKline Company Details
Table 75. GlaxoSmithKline Business Overview
Table 76. GlaxoSmithKline Product
Table 77. GlaxoSmithKline Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020) (Million US$)
Table 78. GlaxoSmithKline Recent Development
Table 79. Pfizer Company Details
Table 80. Pfizer Business Overview
Table 81. Pfizer Product
Table 82. Pfizer Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020) (Million US$)
Table 83. Pfizer Recent Development
Table 84. Novartis Company Details
Table 85. Novartis Business Overview
Table 86. Novartis Product
Table 87. Novartis Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020) (Million US$)
Table 88. Novartis Recent Development
Table 89. Merck Company Details
Table 90. Merck Business Overview
Table 91. Merck Product
Table 92. Merck Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020) (Million US$)
Table 93. Merck Recent Development
Table 94. Janssen Pharmaceuticals Company Details
Table 95. Janssen Pharmaceuticals Business Overview
Table 96. Janssen Pharmaceuticals Product
Table 97. Janssen Pharmaceuticals Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020) (Million US$)
Table 98. Janssen Pharmaceuticals Recent Development
Table 99. AstraZeneca Company Details
Table 100. AstraZeneca Business Overview
Table 101. AstraZeneca Product
Table 102. AstraZeneca Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020) (Million US$)
Table 103. AstraZeneca Recent Development
Table 104. Array BioPharma Company Details
Table 105. Array BioPharma Business Overview
Table 106. Array BioPharma Product
Table 107. Array BioPharma Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020) (Million US$)
Table 108. Array BioPharma Recent Development
Table 109. Vericel Business Overview
Table 110. Vericel Product
Table 111. Vericel Company Details
Table 112. Vericel Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020) (Million US$)
Table 113. Vericel Recent Development
Table 114. Celladon Company Details
Table 115. Celladon Business Overview
Table 116. Celladon Product
Table 117. Celladon Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020) (Million US$)
Table 118. Celladon Recent Development
Table 119. Teva Pharmaceutical Industries Company Details
Table 120. Teva Pharmaceutical Industries Business Overview
Table 121. Teva Pharmaceutical Industries Product
Table 122. Teva Pharmaceutical Industries Revenue in Dilated Cardiomyopathy Treatment Business (2015-2020) (Million US$)
Table 123. Teva Pharmaceutical Industries Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Dilated Cardiomyopathy Treatment Market Share by Type: 2020 VS 2026
Figure 2. Drugs Features
Figure 3. Implantable Devices Features
Figure 4. Global Dilated Cardiomyopathy Treatment Market Share by Application: 2020 VS 2026
Figure 5. Hospitals and Clinics Case Studies
Figure 6. Others Case Studies
Figure 7. Dilated Cardiomyopathy Treatment Report Years Considered
Figure 8. Global Dilated Cardiomyopathy Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 9. Global Dilated Cardiomyopathy Treatment Market Share by Regions: 2020 VS 2026
Figure 10. Global Dilated Cardiomyopathy Treatment Market Share by Regions (2021-2026)
Figure 11. Porter's Five Forces Analysis
Figure 12. Global Dilated Cardiomyopathy Treatment Market Share by Players in 2019
Figure 13. Global Top Dilated Cardiomyopathy Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dilated Cardiomyopathy Treatment as of 2019
Figure 14. The Top 10 and 5 Players Market Share by Dilated Cardiomyopathy Treatment Revenue in 2019
Figure 15. North America Dilated Cardiomyopathy Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 16. Europe Dilated Cardiomyopathy Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. China Dilated Cardiomyopathy Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Japan Dilated Cardiomyopathy Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Southeast Asia Dilated Cardiomyopathy Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. India Dilated Cardiomyopathy Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Central & South America Dilated Cardiomyopathy Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Bottom-up and Top-down Approaches for This Report
Figure 23. Data Triangulation
Figure 24. Key Executives Interviewed
拡張型心筋症の世界市場（～2026年） Dilated Cardiomyopathy (DCM) refers to the cardiac hypertrophy, cannot effectively pump blood. Dilated Cardiomyopathy (DCM) is due to genetic or other disease caused by a heart disease, it respectively affect the ventricles of the heart and heart, the inferior vena chamber and the upper Chambers of …- 心筋症の世界市場（～2026年） Cardiomyopathy refers to diseases of the heart muscle The major factors that contributes in the growth of the market are advancement in understanding and managing cardiomyopathy and rise in incidences of congestive heart failure, coronary heart disease, and heart attack. Further, increasing trend of…
- 肥大型心筋症治療薬の世界市場（～2026年） HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers …
- 肥大型心筋症（HCM）治療薬の世界市場（～2026年） Hypertrophic Cardiomyopathy (HCM) is a condition in which a portion of the heart becomes thickened without an obvious cause. This results in the heart being less able to pump blood effectively. Symptoms vary from none to feeling tired, leg swelling, and shortness of breath. It may also result in che…
- ドライアイ治療薬・装置治療の世界市場（～2026年） Dry eye disease is a condition that affects the tear film and ocular surface. It is medically known as keratoconjunctivitis sicca. It is an ocular disorder caused by the lack of tear fluid to lubricate the eyes. There are primarily two types of dry eye conditions. One is aqueous tear-deficient dry e…